Giorgia Guglielmi
Giorgia Guglielmi is a freelance science writer based in Basel, Switzerland. Specializing in life sciences, medicine, and the relationship between science and society, she has published numerous articles in outlets including Nature, Science, and Scientific American. She holds a PhD in biology from the European Molecular Biology Laboratory and a Master’s in Science Writing from the Massachusetts Institute of Technology. She has received recognition for her work, including the John Kendrew Award in 2020 and an ERC-funded FRONTIERS Media Fellowship in 2025. She has also led lectures and workshops on science communication at institutions such as Harvard University and the University of Zurich.
Tumor microbiotas appear mainly in cancers of the mouth and digestive tract.
Diabetes prevention needs to account for diet-microbiota interactions, because some gut microbes appear to predict diabetes risk differently depending on fiber intake.
Monitoring or reshaping the gut microbiota after adenoma removal could become part of future strategies to reduce colorectal cancer risk.
Repeated head impacts, even if minor, can have biological effects.
The results may inform programs to preserve microbial diversity while delivering essential care.
Targeting deoxycholic acid (DCA)-producing gut bacteria could be a way to slow breast cancer progression.
Microbiota-derived molecules such as IPA may offer a way to strengthen early-life immunity against respiratory viruses.
Monitoring the gut microbiota could in the future help understand, diagnose, or manage Sjögren syndrome.
Microbial communities may be engineered at the protein-expression level because bacteria adjust their protein production in response to specific neighbors.
Sangeribacter muris KT1-3 made sepsis deadlier by amplifying inflammation driven by TLR4.
